US 11673902
Isoindolinone and indazole compounds for the degradation of EGFR
granted A61KA61K31/427A61K31/496
Quick answer
US patent 11673902 (Isoindolinone and indazole compounds for the degradation of EGFR) held by C4 THERAPEUTICS, INC. expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- C4 THERAPEUTICS, INC.
- Grant date
- Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 29
- CPC classes
- A61K, A61K31/427, A61K31/496, A61K31/506, A61K31/5377